CONTACT
+91 80 2808 2808
info@biocon.com
Inside banner
Biocon  /  News  /  Media Stories

MEDIA STORIES

Biocon receives US FDA approval for antifungal drug micafungin

 04-Jun-2024

external_link-01
Aim is to be among top three biosimilars players globally: Biocon Biologics CEO Shreehas Tambe

 27-May-2024

external_link-01
Biocon bets on weight-loss drugs as major growth engine for the business

 21-May-2024

external_link-01
Acceleration of biosimilar business, debt reduction to be key priorties in FY25: Biocon Chief

 18-May-2024

external_link-01
Biocon’s Biosimilar Business Set For Strong Growth: CEO Shreehas Tambe

 18-May-2024

external_link-01
Biocon Group CEO sees enormous opportunities in weight loss drugs market

 17-May-2024

external_link-01
Biocon inks licensing pact with Biomm for diabetes management drug Semaglutide in Brazil

 17-Apr-2024

external_link-01
Biocon becomes the first generics company to get a diabetes drug approval in the UK

 28-Mar-2024

external_link-01
Biocon Biologics Signs 10-Year Deal With Eris Lifesciences To Expand Patient Access

 14-Mar-2024

external_link-01
Biocon Biologics: US Biosimilars Are A Marathon, Not A Sprint

 13-Mar-2024

external_link-01
Biocon Biologics secures Canada market entry date for YESAFILI

 04-Mar-2024

external_link-01
Biocon Biologics Secures US Entry Date For Bmab 1200, A Stelara Biosimilar

 01-Mar-2024

external_link-01
Biocon included in S&P Global Sustainability Yearbook 2024

 20-Feb-2024

external_link-01
Biocon Biologics focusing on market share gains of biosimilars in key markets

 13-Feb-2024

external_link-01
Biocon Biologics inks pact with Sandoz for sale of 2 biosimilar products in Australia

 09-Feb-2024

external_link-01
Biocon Q3FY24 results: Net profit at Rs 660 crore, revenue up 50%

 08-Feb-2024

external_link-01
Biocon gets USFDA approval to market generic anti-cancer medication

 O6-Feb-2024

external_link-01
Budget ’24 | A vision of ‘Viksit Bharat’, driven by inclusion and innovation: Kiran Mazumdar Shaw

 02-Feb-2024

external_link-01
Biocon Group concludes month-long sustainability initiatives with ‘Nature Positive’ campaign

 O3-July-2023

external_link-01
Kiran Mazumdar-Shaw says Biocon in a position to pursue high growth trajectory

17-Mar-2023

external_link-01
Kotak’s alternative investment fund pumps in ₹1,070 cr in Biocon

22-Fab-2023

external_link-01
Biocon Biologics prioritises integration of Viatris assets

16-Feb-2023

external_link-01
Biocon Foundation wins ‘IHW Gold Award for Diseases Screening Initiative of the Year’ for 2022

24-Jan-2023

external_link-01
Biocon Biologics recognised for great managers

 23-Dec-2022

external_link-01
Biocon Biologics appoints Shreehas Tambe as MD & CEO

 05-Dec-2022

external_link-01
‘Science 2022 Top Employer List’ recognises two Indian pharma companies

 02-Nov-2022

external_link-01
Biocon in pact with Japan’s Yoshindo to commercialise two biosimilar assets

17-Oct-2022

external_link-01
Biocon Foundation receives the ‘Mahatma Award 2022 For Excellence in Social Good’

 08-Oct-2022

external_link-01
Never let gender come in the way of your ambitions, dream big: Kiran Mazumdar-Shaw at Yuva Unstoppable event

03-Oct-2022

external_link-01
Biocon’s growth drivers are in place: 5 reasons it is this week’s stock pick

03-Oct-2022

external_link-01
Want to be remembered more than just woman of science: Kiran Mazumdar-Shaw

25-Sep-2022

external_link-01
Mazumdar-Shaw awarded H.K. Firodia Lifetime Achievement Award 2022

25-Sep-2022

external_link-01
Biocon CEO says no intention to sell further stake in Syngene

 07-Sep-2022

external_link-01
Biocon Biologics’ Malaysian unit enters Malaysia Book of Record

 05-Aug-2022

external_link-01
Biocon Biologics’ antibody drug unit in Bengaluru gets EU GMP certificate

 06-July-2022

external_link-01
Biocon Biologics receives EU GMP certification for its new biologics manufacturing facility in Bengaluru

 05-July-2022

external_link-01
Biocon Biologics expects big gains from integration of Viatris business, SII deal

 09-June-2022

external_link-01
Expect regulatory nods for deal with Serum and Viatris to come by H2: Kiran Mazumdar-Shaw, chairperson, Biocon and Biocon Biologics

04-May-2022

external_link-01
Biocon Biologics may close $3.34 billion Viatris deal in Q1

02-May-2022

external_link-01
Eyeing over 15% market share in US for insulin Glargine: Shreehas Tambe

30-April-2022

external_link-01
Biocon Biologics expects R&D expenses to hover between 10-15% in the next financial year

29-April-2022

external_link-01
Biocon arm to buy US company Biosimilar biz for $3.34 billion

01-Mar-2022

external_link-01
Biocon Biologics acquires Viatris for $3.33 billion

01-Mar-2022

external_link-01
Biocon Biologics acquires Viatris’ biosimilars business in $3.3 bn deal

28-Feb-2022

external_link-01
R&D expenditure will rise in the coming quarters: Biocon Biologics MD

25-Jan-2022

external_link-01
Insulins access program for young expanded in Dec quarter: Biocon Biologics MD

24-Jan-2022

external_link-01
Biocon Biologics set to reap biosimilar insulin glargine opportunity in US

22-Jan-2022

external_link-01
The Medicine Box: Kiran Mazumdar-Shaw on biosimilar interchangeable status for Biocon’s diabetes drug

25-Nov-2021

external_link-01
Biocon Biologics, Viatris confirm offering steep savings on long-acting insulin through Walgreens Prescription Savings Club

19-Nov-2021

external_link-01
Walgreens to sell Biocon’s insulin Semglee in the U.S.

19-Nov-2021

external_link-01
Biocon Biologics, Viatris launch interchangeable insulin biosimilar for US

 16-Nov-2021

external_link-01
Biocon starts campaign to treat diabetic children, train healthcare workers

 15-Nov-2021

external_link-01
Access to diabetes care: If not now, then when?

 14-Nov-2021

external_link-01
Biocon Rating: Hold – Vaccines to complement biosimilar portfolio

 20-Sep-2021

external_link-01
Biocon Biologics, Serum Institute Life Sciences announce strategic alliance

 20-Sep-2021

external_link-01
Biocon jumps into vaccines through $4.9bn Serum Institute pact

 20-Sep-2021

external_link-01
Can Serum deal provide a booster dose to Biocon’s target price?

 20-Sep-2021

external_link-01
Interchangeable insulin to help us compete with big insulin makers: Kiran Mazumdar-Shaw

 29-Aug-2021

external_link-01
Vaccines alone will not protect and make the world safer: Biocon chief

 30-Jul-2021

external_link-01
India must use, share Covid data transparently: Kiran Mazumdar-Shaw

 26-Jul-2021

external_link-01
Biocon partners Adagio for licence to make Covid-19 antibody cocktail

 26-Jul-2021

external_link-01
Biocon eyes market share expansion in developed, emerging markets: Kiran Mazumdar-Shaw

 23-Jul-2021

external_link-01
Biocon Q4 profit more than doubles to Rs 254 crore

 29-Apr-2021

external_link-01
Shreehas Tambe named Deputy CEO of Biocon Biologics

 02-Mar-2021

external_link-01
Biocon Biologics, Viatris get CHMP nod for Abevmy

 02-Mar-2021

external_link-01
Biocon Biologics to partner with International Diabetes Federation

 16-Feb-2021

external_link-01
Biocon arm, CHAI in pact on affordable cancer therapies

 04-Feb-2021

external_link-01
Expect Accelerated Growth from Next Fiscal, Says Kiran Mazumdar-Shaw

 25-Jan-2021

external_link-01
Biocon says may have to delay biologics biz IPO

 25-Jan-2020

external_link-01
PANDEMIC PAIN Biocon Chairperson Kiran Mazumdar-Shaw says the Covid impact on business across the value chain has been larger than expected p2

 25-Jan-2020

external_link-01
Biocon Biologics Receives USD 150 Million Capital Injection from Goldman Sachs

08-Nov-2020

external_link-01
India-based company brings affordable insulin to 2 PH towns

23-Oct-2020

external_link-01
Will Biocon’s COVID-19 anti-inflammatory succeed where IL-6 blockers have failed?

 01-Aug-2020

external_link-01
India’s Biocon secures approval to use drug on coronavirus patients

 11-July-2020

external_link-01
Biosimilar drugs can help us reach $1 billion target soon

16-Jun-2020

external_link-01
Kiran Mazumdar-Shaw named EY World Entrepreneur of 2020

 06-Jun-2020

external_link-01
Covid provides larger opportunity to shape the biosimilar landscape

 19-May-2020

external_link-01
Will invest Rs2,000 crore in small molecules in 3-4 years

 16-May-2020

external_link-01
Biocon wins patent case against Sanofi

 12-Mar-2020

external_link-01
Biocon’s cancer biosimilar gets US FDA acceptance for review

 10-Mar-2020

external_link-01
Biocon chief is EY entrepreneur for 2019

 22-Feb-2020

external_link-01
Biocon Biologics Eyes $200M. Plans IPO in 2 Yrs: Mazumdar-Shaw

 27-Jan-2020

external_link-01
Biocon Q3 PBT up 9%

 24-Jan-2020

external_link-01
Biocon optimistic about hitting $1 billion in revenue by FY22 on back of new launches

 08-Jan-2020

external_link-01
Biocon, partner Mylan launch oncology biosimilar trastuzumab in US

11-Dec-2019

external_link-01
USFDA nod to Biocon’s new Bengaluru unit

28-Nov-2019

external_link-01
Biocon, Mylan get nod for pegfilgrastim drug

28-Nov-2019

external_link-01
Indian company makes it to top 10 best employers in biotech category

30-Oct-2019

external_link-01
Insulin at ₹7 will be a gamechanger for us

26-Oct-2019

external_link-01
Life-enabling product like insulin should be made affordable: Shaw

28-Sep-2019

external_link-01
Biocon plans to halve insulin prices

27-Sep-2019

external_link-01
Biocon sets $1 billion target for biologics business

25-Oct-2019

external_link-01
Biocon subsidiary acquires Pfizer’s R&D facility in Chennai

25-Sep-2019

external_link-01
Blueprint for a Healthy India

25-Sep-2019

external_link-01
Ramp-up of biosimilar portfolio to boost Biocon

22-Aug-2019

external_link-01
Our aim is to be a global leader in biosimilars biz: Biocon Biologics CEO

 30-Jul-2019

external_link-01
Biocon’s net rises 86%, revenue 25%

 26-Jul-2019

external_link-01
Biocon net profit grows 72%

 25-Jul-2019

external_link-01
Biosimilars, research key drivers for Biocon

 18-Jun-2019

external_link-01
Trastuzumab’s US launch will be a big opportunity for Biocon-Mylan: Shaw

 18-Jun-2019

external_link-01
Biocon’s Bengaluru biologics units get European agency nod

 15-Jun-2019

external_link-01
The First Lady of Biotech

 08-Jun-2019

external_link-01
Biocon, Mylan to present data for Ogivri at ASCO meeting

 30-May-2019

external_link-01
Canada clears Mylan & Biocon’s Biosimilar

 23-May-2019

external_link-01
Biologics to boost Biocon business, say analyst

 20-May-2019

external_link-01
Biocon drug gets commercial rights to global markets

 09-May-2019

external_link-01
Biosimilars to help Biocon hit $1bn revenue in FY20

 30-Apr-2019

download
Biologics, research services the golden goose for Biocon

 27-Apr-2019

external_link-01
Biocon Q4 net profit up 64% to ₹213.7 crore

 26-Apr-2019

external_link-01
Kiran Mazumdar-Shaw conferred with honorary doctorate from Deakin University, Australia

 18-Apr-2019

external_link-01
Violence,EVM glitches, missing names:Rocky start to election

 12-Apr-2019

external_link-01
Research must be promoted in colleges

 08-Apr-2019

external_link-01
ET Prime celebrates Women’s Excellence in Business & Innovation

 05-Apr-2019

external_link-01
Breakthrough innovation is taking place but we’re not leveraging it

 05-Apr-2019

external_link-01
Kiran Mazumdar-Shaw conferred with Honorary Doctorate

 04-Apr-2019

external_link-01
Biocon Biologics India appoints Dr. Christiane Hamacher as CEO

 01-Apr-2019

external_link-01
Biocon chief stresses on gender equality

 29-Mar-2019

external_link-01
Kiran back as Infy’s independent director

 19-Mar-2019

external_link-01
Govt Should Scale Up Philanthropic Capital

 18-Mar-2019

external_link-01
Cost of select insulin increases up to 20%

 15-Mar-2019

external_link-01
Role of Indian women in Science & Technology

 12-Mar-2019

external_link-01
The growing share of biosimilars revenue is doing wonders for our business

 11-Mar-2019

external_link-01
Biosimilars offer a huge opportunity for Biocon

 08-Mar-2019

external_link-01
Future jobs will be different: Shaw

 07-Mar-2019

external_link-01
Pharma specialist new CEO of Biocon Biologics

 03-Mar-2019

external_link-01
Hamacher is CEO of Biocon Biologics

 02-Mar-2019

external_link-01
In bid to curb profiteering, govt caps margins of 42 cancer drugs

 28-Feb-2019

external_link-01
Shortage of women for leadership roles

 23-Feb-2019

external_link-01
Biocon’s revenue up 43%; Net profit up 136%

 18-Feb-2019

external_link-01
Biocon’s Trastuzumab receives approvals in EU

 13-Feb-2019

external_link-01
Kiran Mazumdar-Shaw elected member of US-based NAE

 09-Feb-2019

external_link-01
Socio-Economic Issues Focus Area of Budget 2019

 04-Feb-2019

external_link-01
Budget Quotes

 02-Feb-2019

external_link-01
Biocon, Mylan announce positive CHMP opinion for Fulphila

 01-Feb-2019

external_link-01
Why Quitting Should Never Be An Option

 31-Jan-2019

external_link-01
Stock Reccos

 29-Jan-2019

external_link-01
Biosimilars make Biocon stand apart

 28-Jan-2019

external_link-01
Biocon Dec quarter net zooms over two-fold to ₹217 Cr

 25-Jan-2019

external_link-01
Top-ranked Karnataka doubles down on skill development

 20-Jan-2019

external_link-01
Biocon focus may shift to non-insulins

 16-Jan-2019

external_link-01
A Briefcase and A Baby

 13-Jan-2019

external_link-01
Kiran Mazumdar-Shaw gets second term as Infosys’ Lead Independent Director

 12-Jan-2019

external_link-01
For India’s healthy billion

 07-Jan-2019

external_link-01
KMS
OUR LEGACY
KEY THERAPEUTIC AREAS
PRODUCTS
Biocon Manufacturing
BUSINESSES
SUSTAINABILITY
Share
Leaving the Biocon site!

You are now leaving the Biocon website for a Biocon affiliate site or third party site that is solely responsible for its content, including its compliance with guidelines applicable in certain geographies. Links to Biocon affiliate sites and third party sites are provided as a resource to our visitors and may not be governed by the same regulatory requirements applicable to this site and unaffiliated third party sites are subject to their own terms and data protection notices and practices. Moreover, if their third party site is subject to other country laws, regulatory requirements, data protection requirements or medical practices may differ between countries and the information provided therein may not be suitable for use in your country.

Agree >>